104 related articles for article (PubMed ID: 1683626)
1. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y
Encephale; 1991; 17(4):255-61. PubMed ID: 1683626
[TBL] [Abstract][Full Text] [Related]
2. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
Singh H; Hunt JI; Vitiello B; Simpson GM
J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
[TBL] [Abstract][Full Text] [Related]
3. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
[TBL] [Abstract][Full Text] [Related]
4. [Incidence of the deficit form in refractory schizophrenia].
Samuelian JC
Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
Langlois-Thery S; Dollfus S; Lesieur P; Petit M
Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
[TBL] [Abstract][Full Text] [Related]
6. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects of clozapine: effect on negative symptoms].
Llorca PM; Lançon C; Auquier P; Bougerol T
Encephale; 1996; 22(4):287-92. PubMed ID: 9035984
[TBL] [Abstract][Full Text] [Related]
8. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia.
Yamagami S; Soejima K
Drugs Exp Clin Res; 1989; 15(4):171-6. PubMed ID: 2570687
[TBL] [Abstract][Full Text] [Related]
9. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
[TBL] [Abstract][Full Text] [Related]
10. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
Woggon B; Bickel P; Schnyder B
Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
[TBL] [Abstract][Full Text] [Related]
11. [Neuroleptic malignant syndrome. Case reports].
Berardi D; Troia M; Veronesi L; Ferrari G
Minerva Psichiatr; 1994 Dec; 35(4):199-219. PubMed ID: 7861943
[TBL] [Abstract][Full Text] [Related]
12. [New chemotherapy approaches to psychoses].
Olié JP; Baylé FJ
Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
[TBL] [Abstract][Full Text] [Related]
13. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
[TBL] [Abstract][Full Text] [Related]
14. [Treatment refractory schizophrenia].
Vanelle JM
Encephale; 1995 Jun; 21 Spec No 3():13-21. PubMed ID: 7628336
[TBL] [Abstract][Full Text] [Related]
15. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
Loas G; Noisette C; Legrand A; Delahousse J
Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
[TBL] [Abstract][Full Text] [Related]
16. [Profile of the action of neuroleptics in deficit schizophrenia].
Vanelle JM
Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
[TBL] [Abstract][Full Text] [Related]
18. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
19. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol monotherapy for treatment-resistant schizophrenia.
Zuardi AW; Hallak JE; Dursun SM; Morais SL; Sanches RF; Musty RE; Crippa JA
J Psychopharmacol; 2006 Sep; 20(5):683-6. PubMed ID: 16401651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]